COVID-variant booster from Sanofi, GSK shows promising results

A COVID-19 vaccine developed by Sanofi SA and GSK PLC to target the Beta strain of the virus produced a stronger antibody response against variants of omicron when given as a booster compared with certain first-generation shots, two studies have found.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.